Azithromycin Reduces Markers of Vascular Damage in Pediatric Patients With Sickle Cell Disease

BACKGROUND: Immunomodulatory effects of macrolides in chronic inflammation are well known. In this study, we tested our hypothesis that azithromycin (AZT) can decrease inflammation in pediatric patients with sickle cell disease (SCD). METHODS: The use of AZT as an anti-inflammatory agent was evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales: Uchakin, Peter N., Sakhalkar, Vishwas S., Dane, Francis C., Uchakina, Olga N., Sheed, Jatayah N., Uphouse, William T., Sakhalkar, Om V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425801/
https://www.ncbi.nlm.nih.gov/pubmed/34527114
http://dx.doi.org/10.14740/jh827

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425801/
https://www.ncbi.nlm.nih.gov/pubmed/34527114
http://dx.doi.org/10.14740/jh827

Ejemplares similares